The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 1, 2012, Pages 47-54

  Kulkarni, Rima ^a   Babaoglu, Kerim ^a   Lansdon, Eric B ^a   Rimsky, Laurence ^b   Van Eygen, Veerle ^b   Picchio, Gaston ^c   Svarovskaia, Evguenia ^a   Miller, Michael D ^a   White, Kirsten L ^a  

^a GILEAD SCIENCES   (United States)

^b TIBOTEC BVBA   (Belgium)

^c Tibotec Inc   (United States)

Author keywords

E138K; emtricitabine; M184I; M184V; rilpivirine; tenofovir

Indexed keywords

EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; NITRILES; PROTEIN CONFORMATION; PYRIMIDINES; RNA, VIRAL; VIRUS REPLICATION;

EID: 83655201316     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823aca74     Document Type: Article

References (40)

1. Harrison L, Castro H, Cane P, et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 2010;24:1917-1922.
2. Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev. 2007;20: 550-578. (Pubitemid 47623768)
3. Kuritzkes DR. Resistance to protease inhibitors. J HIV Ther. 2002;7: 87-91.
4. Svarovskaia ES, Feng JY, Margot NA, et al. The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation. J Acquir Immune Defic Syndr. 2008;48:428-436.
5. Nakahara K, Wakasa-Morimoto C, Kobayashi M, et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009;81:141-146.
6. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010;55: 148-155.
7. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background necleoside or necleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237.
8. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
9. Eron J, Rimsky L, Clotet B, et al. Characterization of the resistance profile of TMC278: 48 week analysis of the Phase 3 studies ECHO and THRIVE [Oral Presentation/PowerPoint]. Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
10. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients failing rilpivirine (RPV, TMC278) in the phase III studies ECHO and THRIVE: 48 week analysis [Poster 9]. Paper presented at: 20th International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies; June 7-11, 2011; Los Cabos, Mexico.
11. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wildtype and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010; 54:718-727.
12. Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-607.
13. Picchio G, Vingerhoets J, Tambuyzer L, et al. Prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States. AIDS Res Hum Retroviruses. [published ahead of print June 11, 2011] doi: 10.1089/AID.2011. 0049.
14. Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1997; 41:2781-2785. (Pubitemid 27524761)
15. Margot NA, Waters JM, Miller MD. In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine. Antimicrob Agents Chemother. 2006;50:4087-4095. (Pubitemid 44865153)
16. Gu Z, Salomon H, Cherrington JM, et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes crossresistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother. 1995;39:1888-1891.
17. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928. (Pubitemid 30165271)
18. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-276. (Pubitemid 28114430)
19. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992; 66:2232-2239.
20. Moser MJ, Ruckstuhl M, Larsen CA, et al. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:3334-3340. (Pubitemid 41060579)
21. Svarovskaia ES, Moser MJ, Bae AS, et al. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol. 2006;44:4237-4241. (Pubitemid 44737281)
22. Wu H, Huang Y, Dykes C, et al. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol. 2006;80:2380-2389. (Pubitemid 43271543)
23. Lansdon EB, Brendza KM, Hung M, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J MedChem. 2010;53:4295-4299.
24. Jacobson MP, Friesner RA, Xiang Z, et al. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol. 2002;320:597-608. (Pubitemid 34753983)
25. Deval J, Navarro JM, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem. 2004; 279:25489-25496. (Pubitemid 38756807)
26. Perez-Bercoff D, Wurtzer S, Compain S, et al. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J Virol. 2007;81:4540-4550. (Pubitemid 46668652)
27. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TCresistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996;15:4040-4049. (Pubitemid 26289813)
28. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol. 2007;81:3037-3041. (Pubitemid 46447070)
29. Hedskog C, Mild M, Jernberg J, et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One. 2010;5:e11345.
30. Frost SD, Nijhuis M, Schuurman R, et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol. 2000;74:6262-6268. (Pubitemid 30429790)
31. Wainberg MA, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995;9:351-357.
32. Crauwels HM, van Schaick E, van Heeswijk RPG, et al. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviralnaive, HIV-1-infected patients in ECHO and THRIVE. Presented at the 10th International Congress on Drug Therapy in HIV Infection; November 7-11, 2010; Glasgow, United Kingdom. Poster P186.
33. Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr. 2011;58:18-22.
34. Sarafianos SG, Das KD, Clark AD, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proc Natl Acad Sci USA. 1999;96:10027-10032. (Pubitemid 29422506)
35. Lindberg J, Sigurdsson S, Lowgren S, et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem. 2002;269: 1670-1677. (Pubitemid 34304466)
36. Chamberlain PP, Ren J, Nichols CE, et al. Crystal structures of Zidovudine-or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J Virol. 2002;76:10015-10019. (Pubitemid 35006540)
37. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
38. Xu H, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase of deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011;85:11300-11308.
39. Hu ZX, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85: 11309-11314.
40. Loveday C, MaCrae E. The prevalence of E138K mutation and other polymorphisms prior to ETR usage in a drug-experienced cohort failing on M1841/V-inducing NRTI regimens. [abstract 49] Antivir Ther. 2011; 16(suppl 1):A62.